PT  - JOURNAL ARTICLE
AU  - HANCOCK, BRYAN M.
AU  - MCGUIRE, KATHLEEN L.
AU  - TSUJI, SHINGO
AU  - REIL, KATHERINE
AU  - HERNANDEZ, VERONICA
AU  - GIACALONE, MATTHEW J.
AU  - GODBEY, W. T.
TI  - A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival
DP  - 2016 Dec 01
TA  - Anticancer Research
PG  - 6243--6248
VI  - 36
IP  - 12
4099  - http://ar.iiarjournals.org/content/36/12/6243.short
4100  - http://ar.iiarjournals.org/content/36/12/6243.full
SO  - Anticancer Res2016 Dec 01; 36
AB  - Background/Aim: VAX014 minicells (VAX014) have been previously characterized as an integrin-specific oncolytic biotherapeutic agent. The present study was designed to evaluate the potential of VAX014 as an immediate post-operative intravesical adjuvant therapy in the treatment of non-muscle invasive bladder cancer (NMIBC). Materials and Methods: The ability of VAX014 to kill a panel of dissociated urothelial carcinoma cell lines was tested in vitro. In vivo experiments were conducted using a single intravesical dose of VAX014 in the anti-implantation variation of the MB49 syngeneic orthotopic bladder cancer model with tumor implantation and overall survival rates serving as study endpoints. Results: VAX014 rapidly killed dissociated urothelial carcinoma cells, while single dose in vivo pharmacology studies demonstrated the dose-dependent ability of VAX014 to prevent tumor implantation and development, ultimately resulting in a significant survival advantage compared to controls. Conclusion: These results suggest that VAX014 holds potential as an immediate post-operative adjuvant therapy in NMIBC.